# Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes

> **NCT04584242** · PHASE4 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 40 (estimated)

## Conditions studied

- Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes

## Interventions

- **DRUG:** gluconon tab 15mg
- **DRUG:** suganon tab 5mg

## Key facts

- **NCT ID:** NCT04584242
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-03
- **Primary completion:** 2022-05
- **Final completion:** 2022-05
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04584242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04584242, "Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04584242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*